Stock search

Ticker or company name

Idexx Laboratories

IDXX · NASDAQ · Health Care

$700,65Down −3,58 (−0,51%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$55,8 bn
Div. yield
—
Year to date
+4,1%
52 weeks: $500,61$769,98

Ratio score

83/100
Ratio would consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

7 ✓ · 1 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM47,247,325,1
Forward P/E33,5—16,2
PEG2,8—2,2
P/S12,010,52,2
EV/EBITDA33,933,617,3
P/FCF42,9—19,5
P/B29,930,33,4

Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 21 analysts

Buy
14
Hold
7
Sell
0

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20263,814,01Up +5,2%
Q2 20264,024,27Up +6,2%
Q1 20263,473,47Up +0,1%
Q4 20252,993,08Up +3,1%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue1,21 bn1,22 bn1,14 bn1,09 bn1,11 bn1,11 bn998 m954 m976 m1,00 bn964 m902 m
EPS4,014,273,473,093,403,632,962,622,802,442,812,31
Margin26,1%27,8%24,4%22,8%24,8%26,5%24,3%22,7%23,9%20,3%24,4%21,6%
FCF421 m323 m234 m326 m371 m152 m208 m233 m192 m215 m168 m217 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $58,4 m.

NameAmountSharesPrice
lane michael4 Nov 2026 · sale$1,15 m1 677$687,46
lane michael4 Nov 2026 · sale$1,42 m2 059$689,70
lane michael4 Nov 2026 · sale$167 148243$687,85
underberg sharon e.4 Nov 2026 · sale$727 9731 055$690,02
underberg sharon e.4 Nov 2026 · sale$1,04 m1 503$689,05
underberg sharon e.4 Nov 2026 · sale$4,37 m6 348$688,25
mazelsky jonathan jay4 Nov 2026 · sale$235 655331$711,95
mazelsky jonathan jay4 Nov 2026 · sale$551 264775$711,31
mazelsky jonathan jay4 Nov 2026 · sale$1,07 m1 501$710,12
mazelsky jonathan jay4 Nov 2026 · sale$921 7021 300$709,00
mazelsky jonathan jay4 Nov 2026 · sale$1,30 m1 840$707,84
mazelsky jonathan jay4 Nov 2026 · sale$593 880840$707,00
mazelsky jonathan jay4 Nov 2026 · sale$169 342240$705,59
mazelsky jonathan jay4 Nov 2026 · sale$2,78 m3 950$703,45
mazelsky jonathan jay4 Nov 2026 · sale$1,50 m2 136$702,21

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Health Care
Exchange
NASDAQ
Country
US
IPO date
21 Jun 1991

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
HUMHumana$461,2561would watch44,0+22,0%0,8%
BDXBecton Dickinson$216,4738would not consider51,8−2,6%4,5%
VEEVVeeva Systems$299,2889would consider47,3+16,5%29,3%
EWEdwards Lifesciences$107,1156would watch60,3+13,4%15,2%
BSXBoston Scientific$43,6983would consider18,4+8,9%16,6%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.